Sengenics and LifeCodexx partner to offer NIPT in Southeast Asia
Konstanz / January 3, 2017 – Sengenics, a leading molecular diagnostics and research services company in Southeastern Asia, and LifeCodexx AG, pioneer in cell-free fetal DNA testing in Europe, announced today that they have formed a partnership in the field of non-invasive prenatal testing (NIPT). Through this cooperation, pregnant women in Malaysia, Singapore, Thailand, Brunei, Vietnam, UAE and Middle East will have access to LifeCodexx’ proprietary PrenaTest® NIPT technologies.
PrenaTest® was Europe’s first NIPT, significantly enhancing prenatal trisomy screening sensitivity, whilst drastically reducing invasive procedure linked pregnancy loss occurrence. The test is performed within Germany in strict conformity with the highest quality standards as per the European Directive on In-vitro Diagnostic Medical Devices. Currently, every 30 minutes a pregnant woman opts for PrenaTest® being today a leading NIPT across Europe and the Middle East.
While initially next generation sequencing technologies have been applied to PrenaTest®, the future test will also use a smart qNIPT technology based on an epigenetic and qPCR approach, for which LifeCodexx recently obtained CE marking. The novel qNIPT will allow increased cost-efficiency and rapid turnaround time with the additional advantage of simplified integration into the lab routines of many laboratories around the world.
Johan Poole-Johnson, Commercial Director of Sengenics commented: “We are proud to be able to provide pregnant women in Southeast Asia access to leading NIPT technologies, ensuring safe and accurate screening for the most common chromosomal disorders in a developing fetus.”
“We are very pleased to expand our footprint into Southeast Asia by teaming up with Sengenics with their long standing expertise in the field of molecular diagnostics services,” added Dr. Michael Lutz, CEO of LifeCodexx. “With this new partnership, our high quality PrenaTest® is now available in close to 50 countries throughout Europe, the Middle East and Southeast Asia.”
PrenaTest® will be offered through the new partnership with immediate effect, and interested patients and clinics should contact Sengenics for more detailed information.
Sengenics is an immuno-diagnostics and therapeutics biotechnology company. Their key focus is leveraging their core patented Immunome protein array technology which was spun out from research that was commercialised as a joint collaboration between the University of Oxford and the University of Cambridge. The four key applications of Immunome are: Discovery of antibody-based therapeutics, discovery of autoantibody biomarkers, on-array kinase and DNA binding assays, and antibody specificity assays.